<!DOCTYPE html> <html lang="en"> <head> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"> <meta name="google-site-verification" content="Pj4WWF5m9cqCcPqkGG75BI1_593zXImuFRpI8TnAous"> <meta http-equiv="Permissions-Policy" content="interest-cohort=()"> <meta charset="utf-8"> <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <title> Tockyを使って、がん免疫療法研究を立ち上げるまで | Masahiro Ono </title> <meta name="author" content="Masahiro Ono"> <meta name="description" content="our cancer immunotherapy Tocky projects"> <meta name="keywords" content="jekyll, jekyll-theme, academic-website, portfolio-website"> <meta property="og:site_name" content="Masahiro Ono"> <meta property="og:type" content="website"> <meta property="og:title" content="Masahiro Ono | Tockyを使って、がん免疫療法研究を立ち上げるまで"> <meta property="og:url" content="https://monotockylab.github.io/japanese/2024-06-10-CancerImmunotherapy/"> <meta property="og:description" content="our cancer immunotherapy Tocky projects"> <meta property="og:image" content="https://monotockylab.github.io/assets/img/MonoTockyLab.png"> <meta property="og:image:url" content="https://monotockylab.github.io/assets/img/MonoTockyLab.png"> <meta property="og:image:secure_url" content="https://monotockylab.github.io/assets/img/MonoTockyLab.png"> <meta property="og:locale" content="en"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@MonoTockyLab"> <meta name="twitter:creator" content="@MonoTockyLab"> <meta name="twitter:title" content="Masahiro Ono | Tockyを使って、がん免疫療法研究を立ち上げるまで"> <meta name="twitter:description" content="our cancer immunotherapy Tocky projects"> <meta name="twitter:image" content="https://monotockylab.github.io/assets/img/MonoTockyLab.png"> <link rel="stylesheet" href="/assets/css/bootstrap.min.css?a4b3f509e79c54a512b890d73235ef04"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/css/mdb.min.css" integrity="sha256-jpjYvU3G3N6nrrBwXJoVEYI/0zw8htfFnhT9ljN3JJw=" crossorigin="anonymous"> <link defer rel="stylesheet" href="/assets/css/academicons.min.css?f0b7046b84e425c55f3463ac249818f5"> <link defer rel="stylesheet" type="text/css" href="https://fonts.googleapis.com/css?family=Roboto:300,400,500,700|Roboto+Slab:100,300,400,500,700|Material+Icons&amp;display=swap"> <link defer rel="stylesheet" href="/assets/css/jekyll-pygments-themes-github.css?591dab5a4e56573bf4ef7fd332894c99" media="" id="highlight_theme_light"> <link rel="shortcut icon" href="/assets/img/favicon.png?fdf6bb598ff65151e77547fe2c57a41a"> <link rel="stylesheet" href="/assets/css/main.css?d41d8cd98f00b204e9800998ecf8427e"> <link rel="canonical" href="https://monotockylab.github.io/japanese/2024-06-10-CancerImmunotherapy/"> <script src="/assets/js/theme.js?a5ca4084d3b81624bcfa01156dae2b8e"></script> <link defer rel="stylesheet" href="/assets/css/jekyll-pygments-themes-native.css?5847e5ed4a4568527aa6cfab446049ca" media="none" id="highlight_theme_dark"> <script>initTheme();</script> </head> <body class="fixed-top-nav "> <header> <nav id="navbar" class="navbar navbar-light navbar-expand-sm fixed-top" role="navigation"> <div class="container"> <a class="navbar-brand title font-weight-lighter" href="/"> Masahiro Ono </a> <button class="navbar-toggler collapsed ml-auto" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar top-bar"></span> <span class="icon-bar middle-bar"></span> <span class="icon-bar bottom-bar"></span> </button> <div class="collapse navbar-collapse text-right" id="navbarNav"> <ul class="navbar-nav ml-auto flex-nowrap"> <li class="nav-item "> <a class="nav-link" href="/">about </a> </li> <li class="nav-item "> <a class="nav-link" href="/blog/">blog </a> </li> <li class="nav-item "> <a class="nav-link" href="/publications/">publications </a> </li> <li class="nav-item "> <a class="nav-link" href="/research/">research </a> </li> <li class="nav-item "> <a class="nav-link" href="/tocky/">Tocky </a> </li> <li class="nav-item "> <a class="nav-link" href="/cv/">cv </a> </li> <li class="nav-item "> <a class="nav-link" href="/researcher/">researcher </a> </li> <li class="nav-item dropdown "> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">submenus </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdown"> <a class="dropdown-item " href="/talks/">talks</a> <div class="dropdown-divider"></div> <a class="dropdown-item " href="/research/">research</a> <div class="dropdown-divider"></div> <a class="dropdown-item " href="/japanese/">日本語</a> <div class="dropdown-divider"></div> <a class="dropdown-item " href="/access/">access</a> </div> </li> <li class="toggle-container"> <button id="light-toggle" title="Change theme"> <i class="ti ti-sun-moon" id="light-toggle-system"></i> <i class="ti ti-moon-filled" id="light-toggle-dark"></i> <i class="ti ti-sun-filled" id="light-toggle-light"></i> </button> </li> </ul> </div> </div> </nav> <progress id="progress" value="0"> <div class="progress-container"> <span class="progress-bar"></span> </div> </progress> </header> <div class="container mt-5" role="main"> <div class="post"> <header class="post-header"> <h1 class="post-title">Tockyを使って、がん免疫療法研究を立ち上げるまで</h1> <p class="post-meta"> June 09, 2024 </p> <p class="post-tags"> <i class="fa-solid fa-calendar fa-sm"></i> 2024   ·   <i class="fa-solid fa-hashtag fa-sm"></i> PD1   <i class="fa-solid fa-hashtag fa-sm"></i> CTLA4   <i class="fa-solid fa-hashtag fa-sm"></i> OX40   <i class="fa-solid fa-hashtag fa-sm"></i> cancer   <i class="fa-solid fa-hashtag fa-sm"></i> immunotherapy     ·   <i class="fa-solid fa-tag fa-sm"></i> 研究内容   </p> </header> <article class="post-content"> <div id="markdown-content"> <p>2017年、Tocky技術とTockyデータ変換方法の開発に成功した後、私たちは最初のトッキー論文を提出し始めました。同時に、Tocky技術の機能を利用した新しいがん免疫療法プロジェクトを立ち上げました。</p> <h3 id="2017年ポンププライミング共同研究グラント">2017年「ポンプ・プライミング」共同研究グラント</h3> <p>2016年、私はがん研究所のコラボレーターであるアラン・メルチャー教授、ケビン・ハリントン教授とともに新たながん免疫療法プロジェクトについて話し合いを始めました。</p> <p>この共同研究の議論が実際にグラント獲得につながります。我々はCancer Research Centre of Excellence（現在のCRUK Convergence Science Centreとして知られています）からのポンプ・プライミング・グラントを獲得することに成功しました。</p> <p>この助成金は2017年9月から始まる1年間のプロジェクトで、重要なマイルストーンとなりました。これにより、Nr4a3-TockyやFoxp3-Tockyなどのツールを使用して、がんに反応するT細胞に対する免疫チェックポイント封鎖の効果を調査するプロジェクトを開始することができました。</p> <h3 id="2019年-博士奨学金の獲得">2019年 博士奨学金の獲得</h3> <p>次の段階として、我々はConvergence Science Centreから<a href="https://www.convergencesciencecentre.ac.uk/research/research-impact/studentship-projects" rel="external nofollow noopener" target="_blank">PD-1阻害に特化した免疫チェックポイント阻害剤の研究を行うための博士学生奨学金グラント</a>を申請しました。この申請は成功し、Tockyツールを使用して免疫チェックポイント阻害による、がん免疫療法のメカニズムを調査するため、新しい博士学生プロジェクトが開始されました。</p> <div class="row"> <div class="col-sm mt-3 mt-md-0 text-center"> <figure> <picture> <source class="responsive-img-srcset" srcset="/assets/img/cruk/2019studentship-480.webp 480w,/assets/img/cruk/2019studentship-800.webp 800w,/assets/img/cruk/2019studentship-1400.webp 1400w," sizes="95vw" type="image/webp"></source> <img src="/assets/img/cruk/2019studentship.jpg" class="img-fluid rounded z-depth-1" width="600" height="auto" data-zoomable="" loading="eager" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </picture> </figure> </div> </div> <div class="caption" style="text-align: center;"> 2019年に新たな博士課程学生を採用した学生プロジェクト。 </div> <p>このプロジェクトは、悪性黒色腫患者におけるT細胞調節メカニズムを探索することにより、がん免疫療法の精度を向上させることを目的としていました。Tocky技術の確立に伴い、このプロジェクトは2つの重要な免疫抑制因子、PD-1およびFoxp3に焦点を当てました。それは、悪性黒色腫および他のがんにおいて標準治療となっている抗PD-1および抗CTLA-4の背後にあるメカニズムを明らかにすることを目指しました。</p> <h3 id="crukプログラム基金賞-2021">CRUKプログラム基金賞 2021</h3> <p>私のがん免疫療法プロジェクトを完全に立ち上げるための大規模な資金を確保するために多くの困難に直面しましたが、その努力はCRUKプログラム基金賞（PFA）の成功した申請で結実しました。</p> <p>この賞のための重要な面接は、英国で最初のロックダウンが始まる直前の2020年3月10日に行われました。</p> <div class="row"> <div class="col-sm mt-3 mt-md-0 text-center"> <figure> <picture> <source class="responsive-img-srcset" srcset="/assets/img/cruk/lockdown-480.webp 480w,/assets/img/cruk/lockdown-800.webp 800w,/assets/img/cruk/lockdown-1400.webp 1400w," sizes="95vw" type="image/webp"></source> <img src="/assets/img/cruk/lockdown.jpg" class="img-fluid rounded z-depth-1" width="450" height="auto" data-zoomable="" loading="eager" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </picture> </figure> </div> </div> <div class="caption" style="text-align: center;"> 2020年3月10日、面接会場の近くにあるスーパーマーケットのトイレットペーパーコーナー。 </div> <p>面接後、私は良い感触を持っていましたが、その結果については、パンデミックによる異常な遅延のため、ほぼ1年待たなければなりませんでした。</p> <h3 id="2021年-最初の共同論文が出版">2021年 最初の共同論文が出版</h3> <p>その間、ICRとの最初の共同がん免疫療法論文が2021年に成功裏に出版されました<a class="citation" href="#RN80">(Bozhanova et al., 2022)</a> 。<a href="https://doi.org/10.1136/jitc-2021-004410" rel="external nofollow noopener" target="_blank">この研究</a>は、Nr4a3-Tocky技術を使用して腫瘍溶解性ウイルス (Oncolytic Virus) 療法のメカニズムを探求しました。</p> <div class="row"> <div class="col-sm mt-3 mt-md-0 text-center"> <figure> <picture> <source class="responsive-img-srcset" srcset="/assets/img/cruk/ov-480.webp 480w,/assets/img/cruk/ov-800.webp 800w,/assets/img/cruk/ov-1400.webp 1400w," sizes="95vw" type="image/webp"></source> <img src="/assets/img/cruk/ov.jpg" class="img-fluid rounded z-depth-1" width="450" height="auto" data-zoomable="" loading="eager" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </picture> </figure> </div> </div> <div class="caption" style="text-align: center;"> 2021年に発表された、ロンドンがん研究所、メルチャー教授・ハリントン教授との共同研究。 </div> <h3 id="2022年7月-最初のプレプリント公開">2022年7月 最初のプレプリント公開</h3> <p>私たちの最初のがん免疫療法研究である免疫チェックポイント阻害に焦点を当てた研究が2022年7月にプレプリントとして公開されました。パンデミックならびに個人的な事情のため、遅延があったものの、これは重要なマイルストーンです。</p> <p>この研究は、Nr4a3-Tocky技術を使用して、抗PD-L1および抗CTLA-4抗体のメカニズムを探求しました。その結果は、抗OX40抗体の仮説とテストにつながり、これはがんに対するT細胞活動に顕著な相乗効果を示しました。</p> <p>私は素晴らしい共同研究者である、ICRのアラン・メルチャー教授とケビン・ハリントン教授、そしてPD-1とLag-3の著名な専門家である岡崎拓教授に感謝しています。</p> <div class="row"> <div class="col-sm mt-3 mt-md-0 text-center"> <figure> <picture> <source class="responsive-img-srcset" srcset="/assets/img/cruk/biorxiv-480.webp 480w,/assets/img/cruk/biorxiv-800.webp 800w,/assets/img/cruk/biorxiv-1400.webp 1400w," sizes="95vw" type="image/webp"></source> <img src="/assets/img/cruk/biorxiv" class="img-fluid rounded z-depth-1" width="750" height="auto" data-zoomable="" loading="eager" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </picture> </figure> </div> </div> <div class="caption" style="text-align: center;"> 我々の2022年bioRxiv論文（Hassan et al 2022)は、Nr4a3 Tockyを使用して、PD1阻害、CTLA-4 阻害、および抗OX40免疫療法がT細胞活動に与える影響を明らかにしました。<a class="citation" href="#RN83">(Hassan et al., 2022)</a>. </div> <p>この取り組みはまだ始まったばかりです。私たちはこのブログ内でまもなく我々のがん免疫療法プロジェクトの全規模について話すことができると期待しています。</p> <hr> <div class="row"> <div class="col-sm mt-3 mt-md-0 text-center"> <figure> <picture> <source class="responsive-img-srcset" srcset="/assets/img/tocky/TockyToki-480.webp 480w,/assets/img/tocky/TockyToki-800.webp 800w,/assets/img/tocky/TockyToki-1400.webp 1400w," sizes="95vw" type="image/webp"></source> <img src="/assets/img/tocky/TockyToki.jpg" class="img-fluid rounded z-depth-1" width="400" height="auto" data-zoomable="" loading="eager" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </picture> </figure> </div> </div> </div> </article> <h2>References</h2> <div class="publications"> <h2 class="bibliography">2022</h2> <ol class="bibliography"> <li> <div class="row"> <div class="col-sm-2 abbr"> </div> <div id="RN80" class="col-sm-8"> <div class="title">CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma</div> <div class="author"> Galabina Bozhanova , Jehanne Hassan , Lizzie Appleton , Victoria Jennings , Shane Foo , Martin McLaughlin , Charleen ML Chan Wah Hak , Emmanuel C Patin , Eva Crespo-Rodriguez , Gabby Baker , Edward Armstrong , Matthew Chiu , Hardev Pandha , Adel Samson , Victoria Roulstone , Joan Kyula , Richard Vile , Fiona Errington-Mais , Malin Pedersen , Kevin Harrington , <em>Masahiro Ono</em>, and Alan Melcher </div> <div class="periodical"> <em>Journal for ImmunoTherapy of Cancer</em>, May 2022 </div> <div class="periodical"> <em style="color: darkgrey;"></em> </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abstract</a> </div> <div class="abstract hidden"> <p>Background Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to improve on the benefit of immune checkpoint inhibitors (ICI).Methods Using a BRAFV600E-driven murine melanoma model, we tested the immunogenicity of HSV/BRAFi in immunocompetent C57BL mice. In addition to standard FACS analysis, we used the ‘Timer of Cell Kinetics and Activity’ system, which can analyze the temporal dynamics of different T cell subsets. This immune data was used to inform the selection of ICI for triple combination therapy, the effects of which were then further characterized using transcriptomics.Results Adding BRAFi treatment to HSV improved anti-tumor effects in vivo but not in vitro. Immune characterization showed HSV or dual therapy led to fewer intratumoral Treg, although with a more activated phenotype, together with more effector CD8 +T cells. Tocky analysis further showed that HSV/BRAFi dual treatment reduced the Tocky signal (reflecting engagement with cognate antigen), in both Treg and conventional subsets of CD4+, but not in CD8 +cells. However, a higher percentage of Treg than of conventional CD4 +maintained frequent engagement with antigens on treatment, reflecting a predominance of suppressive over effector function within the CD4 +compartment. The only T cell subset which correlated with a reduction in tumor growth was within Tocky signal positive conventional CD4+, supporting their therapeutic role. Targeting CD25 high, antigen-engaged Treg with a depleting anti-CD25 ICI, achieved complete cures in 100% of mice with triple therapy. Transcriptomic analysis confirmed reduction in Foxp3 on addition of anti-CD25 to HSV/BRAFi, as well as increases in expression of genes reflecting interferon signaling and cytotoxic activity.Conclusions Combination HSV/BRAFi is an immunogenic therapy for BRAF mutant melanoma, but cannot fully control tumors. Dual therapy results in changes in T cell dynamics within tumors, with relatively maintained antigen signaling in Treg compared with conv CD4+. Antigen-engaged CD4 +effectors correlate with tumor growth control, and depletion of Treg by addition of an anti-CD25 ICI, releasing suppression of conventional CD4 +effectors by Treg, enhances survival and activates immune signaling within tumors.All data relevant to the study are included in the article or uploaded as online supplemental information. Not applicable.</p> </div> </div> </div> </li> <li> <div class="row"> <div class="col-sm-2 abbr"> </div> <div id="RN83" class="col-sm-8"> <div class="title">Single-cell level temporal profiling of tumour-reactive T cells under immune checkpoint blockade</div> <div class="author"> Jehanne Hassan , Elizabeth Appleton , Bahire Kalfaoglu , Malin Pedersen , José Almeida-Santos , Hisashi Kanemaru , Nobuko Irie , Shane Foo , Omnia Reda , Benjy J.Y. Tan , Il-mi Okazaki , Taku Okazaki , Yorifumi Satou , Kevin Harrington , Alan Melcher , and <em>Masahiro Ono</em> </div> <div class="periodical"> <em>bioRxiv</em>, May 2022 </div> <div class="periodical"> <em style="color: darkgrey;"></em> </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abstract</a> <a href="https://doi.org/10.1101/2022.07.19.500582" class="btn btn-sm z-depth-0" role="button" rel="external nofollow noopener" target="_blank">Publication</a> </div> <div class="abstract hidden"> <p>The blockade of the immune checkpoints PD-1 and CTLA-4 enhances T cell response. However, it is largely unknown how antigen-reactive T cells regulate their checkpoint expression in vivo and whether and how the checkpoint blockade can change activation dynamics of tumour-reactive T cells. To address this, here we used Nr4a3-Timer-of-cell-kinetics-and-activity (Tocky), which allows analysis of temporal changes of activated T cells following TCR signalling in vivo. By analysing melanoma-bearing Nr4a3 Tocky mice, we elucidate hidden dynamics of tumour-reactive T cells in the steady-state. Checkpoint blockade depleted highly activated effector Treg, while promoting unique effector T cell populations, and thus differentially modulating activation of tumour-reactive T cell populations. Furthermore, multidimensional analysis and seamless analysis of Tocky and scRNA-seq revealed a full spectrum of T cell dynamics in response to tumour burden and treatment with checkpoint blockade. Lastly, we propose a rational design of combinatorial therapy to further enhance T cell activities.Competing Interest StatementThe authors have declared no competing interest.</p> </div> </div> </div> </li> </ol> </div> <br> <hr> <br> <ul class="list-disc pl-8"></ul> <h2 class="text-3xl font-semibold mb-4 mt-12">Enjoy Reading This Article?</h2> <p class="mb-2">Here are some more articles you might like to read next:</p> <li class="my-2"> <a class="text-pink-700 underline font-semibold hover:text-pink-800" href="/blog/2024/reflections/">reflections on my research history</a> </li> <li class="my-2"> <a class="text-pink-700 underline font-semibold hover:text-pink-800" href="/blog/2024/CancerImmunotherapy/">tocky illuminates mechanisms of immune checkpoint blockade</a> </li> <li class="my-2"> <a class="text-pink-700 underline font-semibold hover:text-pink-800" href="/blog/2024/cca/">journey to tocky via cca</a> </li> <li class="my-2"> <a class="text-pink-700 underline font-semibold hover:text-pink-800" href="/blog/2024/TGN1412/">t-cell dynamics matter</a> </li> <li class="my-2"> <a class="text-pink-700 underline font-semibold hover:text-pink-800" href="/blog/2024/dermatology/">professionalism and official account integrity</a> </li> </div> </div> <footer class="fixed-bottom" role="contentinfo"> <div class="container mt-0"> © Copyright 2024 Masahiro Ono. Powered by <a href="https://jekyllrb.com/" target="_blank" rel="external nofollow noopener">Jekyll</a> with <a href="https://github.com/alshedivat/al-folio" rel="external nofollow noopener" target="_blank">al-folio</a> theme. Hosted by <a href="https://pages.github.com/" target="_blank" rel="external nofollow noopener">GitHub Pages</a>. Last updated: November 24, 2024. </div> </footer> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.0/dist/jquery.min.js" integrity="sha256-/xUj+3OJU5yExlq6GSYGSHk7tPXikynS7ogEvDej/m4=" crossorigin="anonymous"></script> <script src="/assets/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/js/mdb.min.js" integrity="sha256-NdbiivsvWt7VYCt6hYNT3h/th9vSTL4EDWeGs5SN3DA=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/masonry-layout@4.2.2/dist/masonry.pkgd.min.js" integrity="sha256-Nn1q/fx0H7SNLZMQ5Hw5JLaTRZp0yILA/FRexe19VdI=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/imagesloaded@5.0.0/imagesloaded.pkgd.min.js" integrity="sha256-htrLFfZJ6v5udOG+3kNLINIKh2gvoKqwEhHYfTTMICc=" crossorigin="anonymous"></script> <script defer src="/assets/js/masonry.js" type="text/javascript"></script> <script defer src="https://cdn.jsdelivr.net/npm/medium-zoom@1.1.0/dist/medium-zoom.min.js" integrity="sha256-ZgMyDAIYDYGxbcpJcfUnYwNevG/xi9OHKaR/8GK+jWc=" crossorigin="anonymous"></script> <script defer src="/assets/js/zoom.js?85ddb88934d28b74e78031fd54cf8308"></script> <script src="/assets/js/no_defer.js?5d75c11f89cd96294bf5e6dd1ee1bb30"></script> <script defer src="/assets/js/common.js?fcfacfb8c6281f5e68d5a7d348186eb1"></script> <script defer src="/assets/js/copy_code.js?12775fdf7f95e901d7119054556e495f" type="text/javascript"></script> <script defer src="/assets/js/jupyter_new_tab.js?d9f17b6adc2311cbabd747f4538bb15f"></script> <script async src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script async src="https://badge.dimensions.ai/badge.js"></script> <script type="text/javascript">window.MathJax={tex:{tags:"ams"}};</script> <script defer type="text/javascript" id="MathJax-script" src="https://cdn.jsdelivr.net/npm/mathjax@3.2.0/es5/tex-mml-chtml.js"></script> <script defer src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6"></script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-VJHT0Y5RYF"></script> <script>function gtag(){window.dataLayer.push(arguments)}window.dataLayer=window.dataLayer||[],gtag("js",new Date),gtag("config","G-VJHT0Y5RYF");</script> <script type="text/javascript">function progressBarSetup(){"max"in document.createElement("progress")?(initializeProgressElement(),$(document).on("scroll",function(){progressBar.attr({value:getCurrentScrollPosition()})}),$(window).on("resize",initializeProgressElement)):(resizeProgressBar(),$(document).on("scroll",resizeProgressBar),$(window).on("resize",resizeProgressBar))}function getCurrentScrollPosition(){return $(window).scrollTop()}function initializeProgressElement(){let e=$("#navbar").outerHeight(!0);$("body").css({"padding-top":e}),$("progress-container").css({"padding-top":e}),progressBar.css({top:e}),progressBar.attr({max:getDistanceToScroll(),value:getCurrentScrollPosition()})}function getDistanceToScroll(){return $(document).height()-$(window).height()}function resizeProgressBar(){progressBar.css({width:getWidthPercentage()+"%"})}function getWidthPercentage(){return getCurrentScrollPosition()/getDistanceToScroll()*100}const progressBar=$("#progress");window.onload=function(){setTimeout(progressBarSetup,50)};</script> </body> </html>